Research Article

Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği

Volume: 11 Number: 2 June 29, 2021
EN TR

Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği

Abstract

Objective: Management of sudden sensorineural hearing loss still remains unclear in otology. To evaluate our experience medical management of sudden hearing loss with review of the literature. Materials and Methods: In this study, we performed retrospective chart review including 60 patients presenting sudden sensorineural hearing loss (SSNHL) between 2008-2018 years. We included only patients given medical management, and hyperbaric oxygen was not performed in any patients. Pure tone audiometric measurements investigated before (PTA I) and after treatment at two weeks (PTA II) and three months (PTA III). We also performed cranial MRI on all patients to disclose intracranial pathology if it was present. Results: The mean age of our cases of was 49.7 years. No certain etiology was detected in all patients in the study. The improvement of hearing loss in our cases was classified according to Siegel's criteria as follows: Type I (3.3%) in 2 patients, Type II (16.7%) in 10 patients, Type III (33.3%) in 20 patients, Type IV (28) in 28 patients (46.7%). Three mean audiometric measurements were compared statistically with each other (PTA I and PTA II: p <0.05; PTA I and III: p <0.05, PTA II and III: p <0.05). Conclusion: In current study, we found that 60 patients diagnosed as SSNHL and given only medical treatment had positive satisfactory hearing improvement who was observed mainly in that patients with moderate to severe hearing loss and younger ones; however, these results require prospective studies involving a large number of patients.

Keywords

Supporting Institution

Yok

References

  1. 1References 1. 1. Psifidis AD, Psillas GK, Daniilidis JCh. Sudden sensorineural hearing loss: Long-term follow-up results. Otolaryngol Head Neck Surg 2006;134(5):809-15.
  2. 2. DeKleyn A. Sudden complete or partial loss of function of the octavus-system in apparently normal person. Acta Otolaryngol 1944;32:407-25.
  3. 3. Körpinar S, Alkan Z, Yiğit O, Gör AP, Toklu AS, Cakir B, et al. Factors influencing the outcome of idiopathic sudden sensorineural hearing loss treated with hyperbaric oxygen therapy. Eur Arch Otorhinolaryngol. 2011 Jan;268(1):41-7.
  4. 4. Lazarini PR and Camargo AC. Idiopathic sudden sensorineural hearing loss: etiopathogenic aspects. Rev Bras Otorrinolaringol 2006;72(4):554-61.
  5. 5. Yildiz Z, Ulu A, Incesulu A, Ozkaptan Y, Akar N. The Importance of Thrombotic Risk Factors in the Development of Idiopathic Sudden Hearing Loss. Clin Appl Thromb Hemost 2008;14(3):356-9.
  6. 6. Siegel LG. The treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Clin North Am. 1975 Jun;8(2):467-73.
  7. 7. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch Otolaryngol 1980;106:772– 6.
  8. 8. Yeo SW, Lee DH, Jun BC, Park SY, Park YS. Hearing outcome of sudden sensorineural hearing loss: Long-term follow-up. Otolaryngol Head Neck Surg 2007;136(2):221-4.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

June 29, 2021

Submission Date

August 9, 2020

Acceptance Date

March 9, 2021

Published in Issue

Year 2021 Volume: 11 Number: 2

APA
Özdamar, O. İ., & Acar, G. Ö. (2021). Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği. Sakarya Medical Journal, 11(2), 246-252. https://doi.org/10.31832/smj.778364
AMA
1.Özdamar Oİ, Acar GÖ. Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği. Sakarya Medical Journal. 2021;11(2):246-252. doi:10.31832/smj.778364
Chicago
Özdamar, Osman İlkay, and Gül Özbilen Acar. 2021. “Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği”. Sakarya Medical Journal 11 (2): 246-52. https://doi.org/10.31832/smj.778364.
EndNote
Özdamar Oİ, Acar GÖ (June 1, 2021) Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği. Sakarya Medical Journal 11 2 246–252.
IEEE
[1]O. İ. Özdamar and G. Ö. Acar, “Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği”, Sakarya Medical Journal, vol. 11, no. 2, pp. 246–252, June 2021, doi: 10.31832/smj.778364.
ISNAD
Özdamar, Osman İlkay - Acar, Gül Özbilen. “Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği”. Sakarya Medical Journal 11/2 (June 1, 2021): 246-252. https://doi.org/10.31832/smj.778364.
JAMA
1.Özdamar Oİ, Acar GÖ. Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği. Sakarya Medical Journal. 2021;11:246–252.
MLA
Özdamar, Osman İlkay, and Gül Özbilen Acar. “Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği”. Sakarya Medical Journal, vol. 11, no. 2, June 2021, pp. 246-52, doi:10.31832/smj.778364.
Vancouver
1.Osman İlkay Özdamar, Gül Özbilen Acar. Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği. Sakarya Medical Journal. 2021 Jun. 1;11(2):246-52. doi:10.31832/smj.778364

INDEXING & ABSTRACTING & ARCHIVING


  29985  30950  30951 30954 34273


30703 The published articles in SMJ are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.